GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » FDC Ltd (NSE:FDC) » Definitions » Notes Receivable

FDC (NSE:FDC) Notes Receivable : ₹0 Mil (As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is FDC Notes Receivable?

FDC's Notes Receivable for the quarter that ended in Mar. 2024 was ₹0 Mil.


FDC Notes Receivable Historical Data

The historical data trend for FDC's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FDC Notes Receivable Chart

FDC Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

FDC Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

FDC Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


FDC Notes Receivable Related Terms

Thank you for viewing the detailed overview of FDC's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


FDC (NSE:FDC) Business Description

Traded in Other Exchanges
Address
C-3 Skyvistas, Near Versova Police Station, D.N. Nagar, Andheri (West), Mumbai, MH, IND, 400053
FDC Ltd is an Indian-based pharmaceutical company with USFDA and UK-MHRA-approved API and formulations manufacturing facilities. It has its presence in numerous therapeutic segments: Anti-infectives, Gastro-Intestinal, Vitamins/Minerals/Nutrients, Ophthalmology/Otologicals, Cardiac, Dermatology, Respiratory, Gynaecology, and Others. The company's brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm. The majority of the revenue is generated domestically.